Allogeneic adipose-derived mesenchymal stem cell therapy in dogs with refractory atopic dermatitis: clinical efficacy and safety

2018 ◽  
Vol 183 (21) ◽  
pp. 654-654 ◽  
Author(s):  
Antonio José Villatoro ◽  
Manuel Hermida-Prieto ◽  
Viviana Fernández ◽  
Fernando Fariñas ◽  
Cristina Alcoholado ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Global Assessment ◽  
Clinical Signs ◽  
Severity Index ◽  
Positive Outcome ◽  
Efficacy And Safety ◽  
Promising Alternative ◽  
Canine Atopic Dermatitis ◽  
Mesenchymal Stem Cell Therapy ◽  
Common Skin

Canine atopic dermatitis (AD) is a common skin disease with a 10–15 per cent prevalence. Current treatments vary in their efficacy and safety. The immunomodulatory properties of mesenchymal stem cells (MSCs) make them a promising alternative treatment. The aim of this study was to evaluate the therapeutic efficacy and safety of allogeneic canine adipose MSCs (cAd-MSCs) in dogs with refractory AD. Twenty-six dogs, suffering from AD for at least 12 months, not responding to conventional therapy, received an intravenous dose of 1.5×106 cAd-MSCs/kg bodyweight. Clinical signs, haematological and biochemistry profiles, and AD severity were assessed in a six-month follow-up using a validated scoring system (Canine Atopic Dermatitis Extent and Severity Index, version 4 (CADESI-04)). The degree of pruritus was quantified using a validated visual analogue scale, and also owner’s global assessment of treatment efficacy. Twenty-two animals completed the study. Pruritus and CADESI-04 scores decreased significantly after one week or month of treatment, respectively, and remained stable for six months. Owner’s global assessment score was 2.15±1.15 for all the animals in the study. In conclusion, systemic administration of allogeneic cAd-MSCs appeared to be a simple therapy with positive outcome in the remission of clinical signs for AD refractory to conventional medications, for at least six months and with no adverse events.

scholarly journals Long-Term Efficacy and Safety of Intravenous Injection of Clonal Mesenchymal Stem Cells Derived From Bone Marrow in Five Adults With Moderate to Severe Atopic Dermatitis

2020 ◽  
Author(s):  
Hyun-Tae Shin ◽  
Si Hyub Lee ◽  
Hee Seong Yoon ◽  
Ji Hye Heo ◽  
Seon Bok Lee ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Side Effects ◽  
Clinical Response ◽  
Response Assessment ◽  
Severity Index ◽  
Severe Atopic Dermatitis ◽  
Efficacy And Safety ◽  
Mesenchymal Stem Cell Therapy ◽  
Term Efficacy

Abstract Atopic dermatitis is a chronic and relapsing inflammatory skin disease that is treated with immunosuppressants. However, long-term use of immunosuppressants may cause toxicity and severe side effects. To confirm the long-term efficacy and safety of clonal mesenchymal stem cell therapy, we performed investigator-initiated clinical trials and long-term observation in five adult patients with moderate to severe atopic dermatitis that was refractory to conventional treatments. The clinical response assessment values such as eczema area and severity index (EASI) improved significantly at 16 weeks, and 80% (4/5) of the patients achieved EASI-50 after one or two treatment cycles. Patients were observed for long-term efficacy and safety for an average of 38 weeks (range: 16–86 weeks) and showed no serious side effects. Among the cytokines tested, CCL-17, IL-13 and IL-22 significantly decreased at the endpoint of the five participants, two patients who maintained good clinical response over 84 weeks showed increased IL-17 cytokine levels in the blood.

scholarly journals Efficacy of Phototherapy With 308-nm Excimer Light for Skin Microbiome Dysbiosis and Skin Barrier Dysfunction in Canine Atopic Dermatitis

2021 ◽  
Vol 8 ◽  
Author(s):  
Ju-Yong Park ◽  
Seon-Myeong Kim ◽  
Jung-Hyun Kim
Keyword(s):  
Atopic Dermatitis ◽  
Relative Abundance ◽  
Barrier Function ◽  
Therapeutic Option ◽  
Clinical Signs ◽  
Skin Barrier ◽  
Skin Barrier Function ◽  
Skin Microbiome ◽  
Canine Atopic Dermatitis ◽  
Allergic Skin

The management of canine atopic dermatitis, an allergic skin disorder, is challenging. To investigate the effect of phototherapy using a 308-nm excimer light as a topical treatment for canine atopic dermatitis, 10 dogs with canine atopic dermatitis and 10 with non-allergic skin were enrolled in this study. Phototherapy was applied every 7 days for a total of 2 months. The skin microbiome, skin barrier function, and clinical outcomes were evaluated after phototherapy. Phototherapy significantly changed the composition of the skin microbiome of dogs with atopic dermatitis and significantly increased the relative abundance of the phyla Actinobacteria and Cyanobacteria. It significantly alleviated the clinical signs of canine atopic dermatitis without serious adverse effects. Transepidermal water loss, as a measure of skin barrier function, significantly decreased after phototherapy. In addition, phototherapy increased microbial diversity and decreased the relative abundance of Staphylococcus pseudintermedius associated with the severity of canine atopic dermatitis. These results suggest that the excimer light therapy is a suitable and safe therapeutic option for canine atopic dermatitis, which is also a spontaneous animal model of atopic dermatitis.

Efficacy and safety of rush immunotherapy with alumprecipitated allergens in canine atopic dermatitis

2014 ◽  
Vol 42 (03) ◽  
pp. 162-173
Author(s):  
Ralf Mueller ◽  
S. Hobi
Keyword(s):  
Atopic Dermatitis ◽  
Adverse Effects ◽  
Allergen Immunotherapy ◽  
Specific Treatment ◽  
Small Animal ◽  
Common Disease ◽  
Efficacy And Safety ◽  
Canine Atopic Dermatitis ◽  
Rush Immunotherapy ◽  
Clinical Problems

Summary Objectives: Canine atopic dermatitis is a very common disease in small animal practice. Its only specific treatment is allergen immunotherapy. In rush-immunotherapy (RIT) increasing doses of allergen extract are injected subcutaneously in short intervals. Maintenance doses are achieved within one day compared to weeks or months with conventional immunotherapy. The aim of this study was to evaluate the safety and efficacy of RIT with alum-precipitated allergens. Materials and methods: A series of 20 dogs with atopic dermatitis underwent RIT with alum-precipitated allergens. Pruritus and medications at the start of the immunotherapy and 12 months afterwards were compared and adverse effects were recorded. Results: Significant improvement in pruritus (p = 0.0001) and medication scores (p = 0.0004) was noted after approximately 12 months of treatment. The observed clinical response was good to excellent in 70% of the dogs, consistent with other published reports. One dog vomited once during the induction day, with no other clinical problems and completion of the normal protocol. The other 19 dogs showed no adverse effects at all during or after RIT. Conclusion and clinical relevance: RIT with alum-precipitated allergens seems to be a safe and efficacious method to treat dogs with atopic dermatitis.

Clinical efficacy of neural therapy for the treatment of atopic dermatitis in dogs

2008 ◽  
Vol 56 (4) ◽  
pp. 459-469 ◽  
Author(s):  
Adriana Bravo-Monsalvo ◽  
Juan Vázquez-Chagoyán ◽  
Lilia Gutiérrez ◽  
Héctor Sumano
Keyword(s):  
Atopic Dermatitis ◽  
Clinical Efficacy ◽  
Severity Index ◽  
Control Group ◽  
Matched Pairs ◽  
Neural Therapy ◽  
Canine Atopic Dermatitis ◽  
Dermatological Condition ◽  
Before And After ◽  
History Of

The aim of this trial was to assess the clinical efficacy of neural therapy (NT) when treating canine atopic dermatitis. Eighteen dogs (no control group), with at least a 12-month history of having nonseasonal atopic dermatitis, were included. No medication with either glucocorticoids or cyclosporin was allowed during the trial. One set of NT was given by injecting an intravenous dose of 0.1 mg/kg of a 0.7% procaine solution, followed by 10 to 25 intradermal injections of the same solution in a volume of 0.1–0.3 mL per site. Dogs were given 6–13 sets of NT during the therapy. The dermatological condition of each patient was evaluated before and after the treatment using two scales: the pruritus visual analogue scale (PVAS) and the canine atopic dermatitis extent and severity index (CADESI). The reduction of pruritus was statistically significant using a Wilcoxon matched-pairs signed-ranks test (P < 0.001). No adverse side effects were observed. NT seems to be an effective alternative to control signs related to canine atopic dermatitis.

The evaluation of Canine Atopic Dermatitis Extent and Severity Index (CADESI) test in dogs with Atopic Dermatitis (AD) treated with cyclosporine or prednisone

2010 ◽  
Vol 13 (4) ◽  
pp. 681-688 ◽  
Author(s):  
I. Taszkun
Keyword(s):  
Atopic Dermatitis ◽  
Severity Index ◽  
Skin Lesions ◽  
Clinical State ◽  
Point Scale ◽  
Canine Atopic Dermatitis ◽  
Group I ◽  
Oral Preparation ◽  
Sandimmun Neoral ◽  
Anti Inflammatory

The evaluation of Canine Atopic Dermatitis Extent and Severity Index (CADESI) test in dogs with Atopic Dermatitis (AD) treated with cyclosporine or prednisone The purpose of this study was to assess the clinical state of dogs with atopic dermatitis (AD) by use of CADESI test in own modification during the first visit in the Dermatology Consult Room as well as during the treatment. The study was performed in two groups (I-E and II-C) of 20 dogs in each group. In dogs which were qualified to the I-E group, as antiallergic, anti-inflammatory and antipruritic treatment, prednisone (oral preparation Encorton - Polfa Pabianice) at dose 0.5 mg/kg b.w./day was administered, while in dogs qualified to the II-C group - cyclosporine (oral preparation Sandimmun Neoral - Novartis Pharma) at a dose of 5 mg/kg b.w./day; the treatment was continued for 6 weeks in both groups. During the study, skin lesions were assessed in 15 specified body areas using 4 parameters and 5-point scale. In group I-E and II-C the amount of received points in CADESI test was decreased by 82.26% and by 83% respectively, after the treatment. Statistical analyses of the results obtained revealed no statistically significant (P=0.05) differences between means of I-E and II-C groups in consecutive examinations, which indicates comparable clinical efficacy of both drugs. Statistically significant differences (P=0.05) of the parameters assessed were found after secondary dermatoses treatment, and after every two weeks of antipruritic and anti-inflammatory treatment.

Vitamin E supplementation in canine atopic dermatitis: improvement of clinical signs and effects on oxidative stress markers

2014 ◽  
Vol 175 (22) ◽  
pp. 560-560 ◽  
Author(s):  
A. Plevnik Kapun ◽  
J. Salobir ◽  
A. Levart ◽  
G. Tav ar Kalcher ◽  
A. Nemec Svete ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Atopic Dermatitis ◽  
Vitamin E ◽  
Clinical Signs ◽  
Oxidative Stress Markers ◽  
Canine Atopic Dermatitis ◽  
Stress Markers ◽  
Vitamin E Supplementation

scholarly journals Age of Onset and Clinical Signs in Canine Atopic Dermatitis

2012 ◽  
Vol 16 (2) ◽  
pp. 126-134
Author(s):  
Nobuaki ARAI ◽  
Shiho USUI ◽  
Yuzo KOKETSU
Keyword(s):  
Atopic Dermatitis ◽  
Age Of Onset ◽  
Clinical Signs ◽  
Canine Atopic Dermatitis

scholarly journals Fexofenadine Treatment of Atopic Dogs: Preliminary Clinical Results

2006 ◽  
Vol 75 (4) ◽  
pp. 549-555 ◽  
Author(s):  
A. Plevnik ◽  
T. Kotnik ◽  
S. Kobal
Keyword(s):  
Atopic Dermatitis ◽  
Severity Index ◽  
Clinical Results ◽  
Efficacy And Safety ◽  
Time Points ◽  
The Third ◽  
Study Results ◽  
Significant Difference ◽  
Severity Index Score ◽  
The Mean

The purpose of our study was to investigate the efficacy and safety of the antihistamine fexofenadine versus methylprednisolone in dogs with atopic dermatitis. Eight dogs were included in the study and randomly allocated to two groups of four animals. The first group (F) received oral fexofenadine and the second group (M) received methylprednisolone. Over a period of 6 weeks, we evaluated the CADESI (Canine Atopic Dermatitis Extent Severity Index) score and the pruritus score and made measurements of biochemical blood indicators (AP, ALT, AST, urea, creatinine) on three occasions. The study results did not reveal any statistically significant differences compared to baseline in AST, ALT, AP, urea and creatinine values in any of the treated groups and at any of the time points during the treatment (p > 0.112). The mean CADESI values and the severity of pruritus were reduced by more than 50% in both groups during the treatment course. There were no statistically significant differences between group M and group F. A statistically significant difference compared to the baseline was found in the reduction of the CADESI score in group F in the sixth week of treatment (p = 0.011). There was also a significant reduction compared to the baseline in the severity of pruritus ingroup M in the third (p = 0.004) and sixth week of treatment (p = 0.022). Our results indicate the possible use of fexofenadine in the treatment of atopic dermatitis in dogs, as it was demonstrated safe and effective in comparison with methylprednisolone.

Validation of the Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4, a simplified severity scale for assessing skin lesions of atopic dermatitis in dogs

2014 ◽  
Vol 25 (2) ◽  
pp. 77-e25 ◽  
Author(s):  
Thierry Olivry ◽  
Manolis Saridomichelakis ◽  
Tim Nuttall ◽  
Emmanuel Bensignor ◽  
Craig E. Griffin ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Severity Index ◽  
Skin Lesions ◽  
Severity Scale ◽  
Canine Atopic Dermatitis

Fluoxetine (SSRI) treatment of canine atopic dermatitis: a randomized, double-blind, placebo-controlled, crossover trial

2014 ◽  
Vol 17 (2) ◽  
pp. 371-373 ◽  
Author(s):  
M. Fujimura ◽  
H. Ishimaru ◽  
Y. Nakatsuji
Keyword(s):  
Atopic Dermatitis ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Crossover Trial ◽  
Severity Index ◽  
Base Line ◽  
Double Blind ◽  
Canine Atopic Dermatitis ◽  
Double Blind Placebo ◽  
Significant Difference ◽  
Ssri Treatment

Abstract This study investigated effects of a fluoxetine (selective serotonin reuptake inhibitors; SSRI, 1 mg/kg) on pruritus in canine atopic dermatitis (CAD). After 4-weeks of base-line observation, 8 dogs with CAD entered a 2-months randomized, double-blind, placebo-controlled, crossover trial comparing fluoxetine with placebo. Clinical efficacy was evaluated using a Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) and Pruritus Visual Analog Scale (PVAS). Six dogs completed the study [two out of eight dogs (both of them were Shiba Inu) dropped out from the study due to a depression]. CADESI-03 and PVAS between fluoxetine and placebo showed no significant difference statistically (P>0.05 and P>0.05 respectively). Fluoxetine showed no efficacy on pruritus in CAD. Further researches are needed for the treatment on pruritus of CAD

Sign in / Sign up

Export Citation Format

Share Document